157 related articles for article (PubMed ID: 23852501)
41. [High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
Provencio M; Fayad LE
Med Clin (Barc); 2008 Jan; 130(2):60-5. PubMed ID: 18221676
[No Abstract] [Full Text] [Related]
42. ECAPP chemotherapy for lymphoma.
Debranin CO
Am J Clin Oncol; 1990 Apr; 13(2):181-2. PubMed ID: 2180275
[No Abstract] [Full Text] [Related]
43. [Treatment of large cell lymphoma].
Cohen Y; Epelbaum R; Ben-Shahar M; Haim N; Ron Y
Harefuah; 1989 Dec; 117(12):417-20. PubMed ID: 2695424
[TBL] [Abstract][Full Text] [Related]
44. The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
Weick JK; Antunez A; Kraus TA; Fabian CJ; Dixon D
Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1205-7. PubMed ID: 6347997
[TBL] [Abstract][Full Text] [Related]
45. New treatment strategies for aggressive lymphoma.
Younes A
Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
[TBL] [Abstract][Full Text] [Related]
46. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
47. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
48. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Copson E
Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
[No Abstract] [Full Text] [Related]
49. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
50. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
[TBL] [Abstract][Full Text] [Related]
51. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Fisher RI
Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
[TBL] [Abstract][Full Text] [Related]
52. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Linch DC; Vaughan Hudson B; Hancock BW; Hoskin PJ; Cunningham DC; Newland AC; Milligan DW; Stevenson PA; Wood JK; MacLennan KA; Anderson L; Gregory WM; Vaughan Hudson G
Br J Cancer; 1996 Jul; 74(2):318-22. PubMed ID: 8688344
[TBL] [Abstract][Full Text] [Related]
53. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma.
Epelbaum R; Haim N; Ben-Shahar M; Ron Y; Cohen Y
Isr J Med Sci; 1988; 24(9-10):533-8. PubMed ID: 3060443
[TBL] [Abstract][Full Text] [Related]
54. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
Coiffier B
Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
[TBL] [Abstract][Full Text] [Related]
55. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
[TBL] [Abstract][Full Text] [Related]
56. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.
DiJoseph JF; Dougher MM; Evans DY; Zhou BB; Damle NK
Cancer Chemother Pharmacol; 2011 Apr; 67(4):741-9. PubMed ID: 20521053
[TBL] [Abstract][Full Text] [Related]
57. A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma.
Bishop JF; Wiernik PH; Wesley MN; Kaplan RS; Diggs CH; Barcos MP; Sutherland JC
Leukemia; 1987 Jun; 1(6):508-13. PubMed ID: 3669768
[TBL] [Abstract][Full Text] [Related]
58. The role of mitoxantrone in non-Hodgkin's lymphoma.
Armitage JO
Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
[TBL] [Abstract][Full Text] [Related]
59. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome.
Vaisheva F; Delbes G; Hales BF; Robaire B
J Androl; 2007; 28(4):578-87. PubMed ID: 17409468
[TBL] [Abstract][Full Text] [Related]
60. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
